Core Viewpoint - West Red Lake Gold Mines Ltd. reports positive reconciliation results from the bulk sample program at its Madsen Mine, indicating it is on track to become a high-grade gold mine in 2025 [1][2] Summary by Sections Company Overview - West Red Lake Gold Mines Ltd. is focused on advancing its flagship Madsen Gold Mine in the Red Lake Gold District of Ontario, which has historically produced over 30 million ounces of gold [14] Bulk Sample Program Results - The bulk sample included material from three main resource zones: Austin, South Austin, and McVeigh, with a total tonnage of 14,490 tonnes producing 2,664 ounces of gold [2][6] - The average grade of the bulk sample was 5.72 grams per tonne (g/t) gold, slightly above the predicted grade of 5.68 g/t [6] - Reconciliation results showed close alignment between predicted and actual grades and tonnages, with overall reconciliation at 95.5% for tonnage and 100.7% for grade [5][7] Mining Methodology - The bulk sample was mined using the long hole retreat mining method, which allows for efficient extraction and lower operational costs [9][10] - Each stope was definition drilled and engineered based on updated models to maximize economic extraction [9][11] Processing Details - The Madsen Mill employs a comprehensive processing method including primary crushing, grinding, gravity concentration, and cyanide leaching, achieving an average gold recovery of 95% [12] Future Outlook - The company anticipates ramping up operations at the Madsen Mine, leveraging the successful bulk sample results to enhance production and overall economics compared to the Prefeasibility Study [2][6]

Core Viewpoint - Kalmar has launched Kalmar One, a standalone automation solution designed to meet the growing demand for a modular and equipment-type agnostic fleet management system in terminal operations [1][4]. Group 1: Product Features - Kalmar One is an OEM and equipment type-agnostic solution that allows terminal operators to integrate and optimize their operations through a single system, standardizing automation solutions across multiple terminals [2][11]. - The solution provides a seamless interface between the terminal operating system and automated equipment, enabling terminals to maximize the efficiency of their automated assets while reducing costs [4][9]. Group 2: Key Benefits - No vendor lock: Kalmar One can interface with any brand of automated equipment, allowing customers to choose their equipment and automation suppliers independently [9]. - Optimized operations: The system enhances the end-to-end logistics flow from stack to quay, ensuring optimal performance on both quayside and landside [9]. - Scalability and flexibility: Kalmar One is modular, allowing businesses to scale their automated operations as needed and add new equipment as their fleet expands, supporting various levels of automation [9]. Group 3: Company Overview - Kalmar operates globally in over 120 countries, employing approximately 5,200 people, and reported sales of approximately EUR 1.7 billion in 2024 [5].

Financial Standing - OP Mortgage Bank (OP MB) reported intermediary loans and bonds issued totaling EUR 14,800 million at the end of March 2025 [2][3] - The operating profit for the period was EUR 1.7 million, a decrease from EUR 2.3 million in the previous year [4] Capital Adequacy - OP MB's Common Equity Tier 1 (CET1) ratio decreased to 372.0% from 797.0% due to an increase in total risk exposure amount following regulatory changes [8][11] - The total risk exposure amount increased significantly to EUR 98,034 thousand from EUR 45,755 thousand [10][11] Collateralisation of Bonds - The cover pool for the Euro Medium Term Covered Bond (Premium) programme included EUR 6,882 million in loans as collateral, with overcollateralisation exceeding the minimum requirement [6] - The Euro Medium Term Covered Note programme had a cover pool of EUR 9,468 million, also exceeding the minimum requirement [7] Risk Profile - OP MB has a strong capital base and risk-bearing capacity, with key credit risk indicators showing stable credit risk exposure [28] - The liquidity coverage ratio (LCR) for OP Financial Group was reported at 202%, indicating strong liquidity management [29] Outlook - The global economic outlook is weakening, with the Finnish economy expected to grow less than previously anticipated, leading to increased uncertainty [32] - OP MB's capital adequacy is expected to remain strong, allowing for future issuance of covered bonds [33]

Core Insights - Honka has developed unique interior styles that complement modern log home structures, providing customers with a comprehensive design concept for creating their ideal interiors [1][5] - The interior styles are inspired by natural elements and current design trends, featuring earthy hues, pastel colors, and luxurious bronze tones [4][10] Company Overview - Honkarakenne Oyj manufactures high-quality, healthy, and ecological log homes, holiday homes, and public buildings from Finnish solid wood, with a total of 90,000 buildings delivered to over 50 countries [14] - In 2024, the company's net sales reached EUR 36.7 million, with exports accounting for 29% of total sales [14] Interior Design Styles - The interior styles include Soft Modern, Nordic Forest, and Mystic Wood, each offering distinct aesthetics and design solutions [6][8][10] - Soft Modern features light pastel shades and sandy tones, while Nordic Forest draws inspiration from the Finnish forest with natural tones and classic oak flooring [8][9] - Mystic Wood is characterized by deep autumnal shades and luxurious bronze detailing, appealing to those seeking a bolder design [10][11] Material Choices - Honka emphasizes healthy material choices, utilizing M1-rated clean materials to minimize synthetic contaminants in indoor air, enhancing living comfort and health [12] - The company positions itself as a pioneer in healthy living with its Honka Healthy House™ log houses, promoting well-being [12] Marketing and Resources - The Honka Look Book, a 100-page inspiration book, showcases the interior styles with attractive design images and is available to customers through local representatives [13]

Core Viewpoint - Intchains Group Limited is set to release its unaudited financial results for the first quarter of 2025, which ended on March 31, 2025, highlighting its ongoing activities in altcoin mining, Ethereum-based cryptocurrency acquisition, and Web3 application development [1]. Group 1 - The earnings conference call will take place on May 22, 2025, at 8:00 PM U.S. Eastern Time, allowing stakeholders to discuss the financial results [2]. - Participants must register in advance using a provided link to receive dial-in numbers and a personal access PIN for the conference call [2]. - A live and archived webcast of the conference call will be available on the Company's investor relations website [3]. Group 2 - Intchains Group Limited focuses on providing altcoin mining products, acquiring and holding Ethereum-based cryptocurrencies, and developing innovative Web3 applications [4]. - For further inquiries, the Company has provided contact information for investor relations [5].

Core Insights - Umecrine Cognition, a portfolio company of Karolinska Development, is presenting new clinical scale data for Primary Biliary Cholangitis (PBC) at the EASL Congress 2025 in Amsterdam [1][2]. Company Overview - Karolinska Development AB holds a 73% ownership stake in Umecrine Cognition [5]. - The company focuses on identifying and investing in breakthrough medical innovations in the Nordic region, aiming to develop these into commercial products [6][8]. Drug Development - Umecrine Cognition is developing golexanolone, a drug candidate currently in a Phase 2a clinical study for PBC [2]. - The newly developed CGI-S-PBC™ scale is designed to evaluate symptom severity in PBC patients, which cannot be measured by conventional laboratory tests [3]. Clinical Research - The CGI-S-PBC™ scale expands on the PBC-40 patient-reported outcome measure and has been validated in two separate studies [3]. - Abstracts summarizing the validation and implementation of CGI-S-PBC™ will be presented at the EASL Congress, focusing on its role as a clinical trials outcome tool [4].

Core Points - Suominen Corporation is launching a cost-saving program aimed at securing profitable growth and enhancing long-term competitiveness [1][2] - The program is expected to generate savings of approximately EUR 10 million over the next 24 months [3] - The initiative may impact up to 60 positions globally, pending local consultation procedures [3] Company Overview - Suominen manufactures nonwovens as roll goods for wipes and other applications, with a vision to lead in nonwovens innovation and sustainability [4] - In 2024, Suominen reported net sales of EUR 462.3 million and employs over 700 professionals across Europe and the Americas [4] - The company's shares are listed on Nasdaq Helsinki [4]

Suominen Corporation’s Interim Report on May 7, 2025, at 9:30 a.m. (EEST)Suominen Corporation’s Interim Report for January 1 – March 31, 2025: Navigating a challenging environment KEY FIGURES 1-3/1-3/1-12/ 202520242024Net sales, EUR million117.5113.6462.3Comparable EBITDA, EUR million4.14.517.0Comparable EBITDA, %3.53.93.7EBITDA, EUR million4.14.717.2EBITDA, %<td style="width:89.34px;;text-align ...

Montrouge, May 7, 2025 CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF EUR 750,000,000 Subordinated Fixed Rate Resettable Notes issued on June 5, 2020 (ISIN: FR0013516184)* Crédit Agricole S.A. (the “Issuer”) announces today the redemption (the “Redemption”) with effect on June 5, 2025 (the “Redemption Date”) of all of its outstanding EUR 750,000,000 Subordinated Fixed Rate Resettable Notes issued on June 5, 2020 (ISIN: FR0013516184) (the “Notes”) pursuant to Condition 6(e) (Redemption at the Option of the Iss ...

Core Viewpoint - Monopar Therapeutics Inc. is presenting promising long-term efficacy and safety data for its drug candidate ALXN1840 for Wilson disease at the EASL International Liver Congress 2025, indicating its potential as a therapeutic option for patients with this rare genetic condition [1][2][3] Group 1: Efficacy and Safety Data - The efficacy data were pooled from three clinical trials involving a total of 255 patients, while safety data were derived from an additional trial with 266 patients [2] - The median treatment duration for efficacy was 961 days (approximately 2.63 years) and for safety was 943.5 days (approximately 2.58 years) [2] - Sustained improvements were observed in the Unified Wilson Disease Rating Scale (UWDRS) for both patient-reported and clinician-assessed symptoms [6] - There was a significant increase in copper mobilization, evidenced by a sustained increase in directly measured non-ceruloplasmin-bound copper (dNCC) [6] - Improvements were noted on the Clinical Global Impression – Improvement (CGI-I) scale for ALXN1840 compared to standard care [6] - The New Wilson Index showed improvement for patients treated with ALXN1840, based on various clinical parameters [6] - Patient-reported convenience and effectiveness of ALXN1840 were higher compared to standard care, especially among those transitioning from standard care to ALXN1840 [6] - Fewer than 5% of patients experienced drug-related serious adverse events, with no cases reported for renal or urinary system issues [6] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments, including ALXN1840 for Wilson disease and various radiopharmaceutical programs for advanced cancers [4]